Tumor mutation burden in biliary tract cancers with ERBB family or DNA damage repair gene mutations. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not ...
Please provide your email address to receive an email when new articles are posted on . Tapering regimens were linked to significantly higher flare risk among patients in RA remission. The results ...
The US Food and Drug Administration (FDA) on Monday finalized guidance to pharmaceutical and biotech sponsors looking for more advice on when non-inferiority studies demonstrating effectiveness of an ...
Repros Therapeutics Androxal Shows Noninferiority In Interim Phase 3 Analysis THE WOODLANDS, Texas -- Repros Therapeutics Inc. announced interim results of a U.S. Phase 3 study of Androxalâ„¢, an oral ...
With very low certainty of evidence, WHO has conditionally recommended two 6-month or 9-month regimens for pre-extensively drug-resistant (pre-XDR) tuberculosis: one comprising bedaquiline, pretomanid ...
ONS-5010 shows non-inferiority to Lucentis at 12 weeks; BLA resubmission planned for Q1 2025, with $20.4M in proceeds expected. ONS-5010 demonstrated non-inferiority to ranibizumab at week 12, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results